Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer

Albert C. Koong, Erin Christofferson, Quynh Thu Le, Karyn A. Goodman, Anthony Ho, Timothy Kuo, James M. Ford, George A. Fisher, Ralph Greco, Jeffrey Norton, George P. Yang

Research output: Contribution to journalArticlepeer-review

280 Scopus citations

Abstract

Purpose: To determine the efficacy of concurrent 5-fluorouracil (5-FU) and intensity-modulated radiotherapy (IMRT) followed by body stereotactic radiosurgery (SRS) in patients with locally advanced pancreatic cancer. Methods and Materials: In this prospective study, all patients (19) had pathologically confirmed adenocarcinoma and were uniformly staged. Our treatment protocol consisted of 45 Gy IMRT with concurrent 5-FU followed by a 25 Gy SRS boost to the primary tumor. Results: Sixteen patients completed the planned therapy. Two patients experienced Grade 3 toxicity (none had more than Grade 3 toxicity). Fifteen of these 16 patients were free from local progression until death. Median overall survival was 33 weeks. Conclusions: Concurrent IMRT and 5-FU followed by SRS in patients with locally advanced pancreatic cancer results in excellent local control, but does not improve overall survival and is associated with more toxicity than SRS, alone.

Original languageEnglish (US)
Pages (from-to)320-323
Number of pages4
JournalInternational Journal of Radiation Oncology Biology Physics
Volume63
Issue number2
DOIs
StatePublished - Oct 1 2005

Keywords

  • Body stereotactic radiosurgery
  • Image guided radiotherapy
  • Intensity modulated radiation therapy
  • Pancreatic cancer
  • Phase II

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this